266 related articles for article (PubMed ID: 30226569)
41. Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance.
Hill DP; Harper A; Malcolm J; McAndrews MS; Mockus SM; Patterson SE; Reynolds T; Baker EJ; Bult CJ; Chesler EJ; Blake JA
BMC Cancer; 2019 Nov; 19(1):1039. PubMed ID: 31684899
[TBL] [Abstract][Full Text] [Related]
42. Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library.
Fujita T; Mizukami T; Okawara T; Inoue K; Fujimori M
Breast Cancer; 2014 Nov; 21(6):738-47. PubMed ID: 23456737
[TBL] [Abstract][Full Text] [Related]
43. The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.
Wu X; Zahari MS; Renuse S; Kelkar DS; Barbhuiya MA; Rojas PL; Stearns V; Gabrielson E; Malla P; Sukumar S; Mahajan NP; Pandey A
Oncotarget; 2017 Jan; 8(2):2971-2983. PubMed ID: 27902967
[TBL] [Abstract][Full Text] [Related]
44. Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1.
Speyer CL; Nassar MA; Hachem AH; Bukhsh MA; Jafry WS; Khansa RM; Gorski DH
Breast Cancer Res Treat; 2016 Jun; 157(2):217-228. PubMed ID: 27146584
[TBL] [Abstract][Full Text] [Related]
45. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells.
Torki S; Soltani A; Shirzad H; Esmaeil N; Ghatrehsamani M
Biomed Pharmacother; 2017 Aug; 92():39-45. PubMed ID: 28528184
[TBL] [Abstract][Full Text] [Related]
46. Identification of FOXE3 transcription factor as a potent oncogenic factor in triple-negative breast cancer.
Wang H; Yang T; Yuan Y; Sun X
Biochem Biophys Res Commun; 2020 Feb; 523(1):78-85. PubMed ID: 31831170
[TBL] [Abstract][Full Text] [Related]
47. Knockdown of SASS6 reduces growth of MDA‑MB‑231 triple‑negative breast cancer cells through arrest of the cell cycle at the G2/M phase.
Du L; Jing J; Wang Y; Xu X; Sun T; Shi Y; Wang W; Tian B; Han C; Zhao X; Chang H
Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33907854
[TBL] [Abstract][Full Text] [Related]
48. Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells.
Sulaiman A; McGarry S; Chambers J; Al-Kadi E; Phan A; Li L; Mediratta K; Dimitroulakos J; Addison C; Li X; Wang L
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32806648
[TBL] [Abstract][Full Text] [Related]
49. Long noncoding RNA GAS5 suppresses triple negative breast cancer progression through inhibition of proliferation and invasion by competitively binding miR-196a-5p.
Li S; Zhou J; Wang Z; Wang P; Gao X; Wang Y
Biomed Pharmacother; 2018 Aug; 104():451-457. PubMed ID: 29793177
[TBL] [Abstract][Full Text] [Related]
50. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
51. CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers.
Cheriyan VT; Muthu M; Patel K; Sekhar S; Rajeswaran W; Larsen SD; Polin L; Levi E; Singh M; Rishi AK
Oncotarget; 2016 Nov; 7(45):73370-73388. PubMed ID: 27687593
[TBL] [Abstract][Full Text] [Related]
52. Silencing GOLPH3 gene expression reverses resistance to cisplatin in HT29 colon cancer cells via multiple signaling pathways.
Zhou ZP; Wang LP; Hong ZS; Qiu CZ; Wang MZ; Chen ZX; Tang LF; Yu WS; Wang CX
Int J Oncol; 2018 Sep; 53(3):1183-1192. PubMed ID: 30015866
[TBL] [Abstract][Full Text] [Related]
53. Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.
Quintero M; Adamoski D; Reis LMD; Ascenção CFR; Oliveira KRS; Gonçalves KA; Dias MM; Carazzolle MF; Dias SMG
BMC Cancer; 2017 Nov; 17(1):727. PubMed ID: 29115931
[TBL] [Abstract][Full Text] [Related]
54. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
55. Mithramycin A suppresses basal triple-negative breast cancer cell survival partially via down-regulating Krüppel-like factor 5 transcription by Sp1.
Liu R; Zhi X; Zhou Z; Zhang H; Yang R; Zou T; Chen C
Sci Rep; 2018 Jan; 8(1):1138. PubMed ID: 29348684
[TBL] [Abstract][Full Text] [Related]
56. Filamin A (FLNA) modulates chemosensitivity to docetaxel in triple-negative breast cancer through the MAPK/ERK pathway.
Zhao P; Ma W; Hu Z; Zang L; Tian Z; Zhang K
Tumour Biol; 2016 Apr; 37(4):5107-15. PubMed ID: 26546439
[TBL] [Abstract][Full Text] [Related]
57. Knockdown of miR-182 promotes apoptosis via regulating RIP1 deubiquitination in TNF-α-treated triple-negative breast cancer cells.
Wo L; Lu D; Gu X
Tumour Biol; 2016 Oct; 37(10):13733-13742. PubMed ID: 27476169
[TBL] [Abstract][Full Text] [Related]
58. Long non-coding RNA MALAT1 promotes proliferation and invasion via targeting miR-129-5p in triple-negative breast cancer.
Zuo Y; Li Y; Zhou Z; Ma M; Fu K
Biomed Pharmacother; 2017 Nov; 95():922-928. PubMed ID: 28915533
[TBL] [Abstract][Full Text] [Related]
59. Next‑generation sequencing analysis reveals that MTH‑3, a novel curcuminoid derivative, suppresses the invasion of MDA‑MB‑231 triple‑negative breast adenocarcinoma cells.
Chiu YJ; Tsai FJ; Bau DT; Chang LC; Hsieh MT; Lu CC; Kuo SC; Yang JS
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34013378
[TBL] [Abstract][Full Text] [Related]
60. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
